3-hydroxybutyric acid has been researched along with Alzheimer Disease in 21 studies
3-Hydroxybutyric Acid: BUTYRIC ACID substituted in the beta or 3 position. It is one of the ketone bodies produced in the liver.
3-hydroxybutyric acid : A straight-chain 3-hydroxy monocarboxylic acid comprising a butyric acid core with a single hydroxy substituent in the 3- position; a ketone body whose levels are raised during ketosis, used as an energy source by the brain during fasting in humans. Also used to synthesise biodegradable plastics.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "SH-SY5Y cells (human neuroblastoma cell line) were exposed to an inhibitor (WZB117) of several types of glucose transporters." | 4.31 | GLUT inhibitor WZB117 induces cytotoxicity with increased production of amyloid-beta peptide in SH-SY5Y cells preventable by beta-hydroxybutyrate: implications in Alzheimer's disease. ( Chakrabarti, S; Chakrabarti, SS; Chandan, G; Ganguly, U; Pal, S; Saini, AK; Saini, RV; Singh, S, 2023) |
| "It is widely accepted that ketosis (increased blood ketone body levels, e." | 2.72 | Beneficial Effects of Exogenous Ketogenic Supplements on Aging Processes and Age-Related Neurodegenerative Diseases. ( Ari, C; Brunner, B; Kovács, Z, 2021) |
| "Donepezil is a first-line acetylcholinesterase inhibitor used for the treatment of AD that has been found, in addition to its potent acetylcholinesterase inhibitory effect, to act through other non-cholinergic mechanisms such as affecting mitochondrial biogenesis through peroxisome proliferator-activated receptor gamma coactivator (PGC1α)." | 1.48 | Acetylcholinesterase Inhibitor Donepezil Effects on Plasma β-Hydroxybutyrate Levels in the Treatment of Alzheimer's Disease. ( Chen, L; Fu, J; Guo, C; Huang, J; Huo, Y; Lu, J; Wan, L; Xin, B; Yang, Q; Zhong, Y, 2018) |
| "Sporadic Alzheimer's disease (AD) is responsible for 60%-80% of dementia cases, and the most opportune time for preventive intervention is in the earliest stage of its preclinical phase." | 1.43 | Ketones block amyloid entry and improve cognition in an Alzheimer's model. ( Dharshaun, T; Eisenberg, D; Gao, M; Han, P; Maalouf, M; Reiman, EM; Ryan, C; Schweizer, FE; Shi, J; Whitelegge, J; Wu, J; Yin, JX; Zhao, M, 2016) |
| "KME-induced hyperketonemia is robust, convenient, and safe, and the ester can be taken as an oral supplement without changing the habitual diet." | 1.42 | A new way to produce hyperketonemia: use of ketone ester in a case of Alzheimer's disease. ( Kashiwaya, Y; King, MT; Newport, MT; VanItallie, TB; Veech, RL, 2015) |
| "Alzheimer's disease is a neurodegenerative disorder associated with the deposition of the peptide amyloid-beta (Aβ) in senile plaques and cerebral vasculature." | 1.42 | The neuroprotective effects of β-hydroxybutyrate on Aβ-injected rat hippocampus in vivo and in Aβ-treated PC-12 cells in vitro. ( Liu, F; Tian, W; Wei, T; Xie, G, 2015) |
| "Patients with Alzheimer's disease (AD) and matched controls fasted for 24 hours, and serial glucose, pyruvate, lactate, beta-hydroxybutyrate, acetoacetate, insulin, and glucagon levels were measured." | 1.27 | Metabolic changes in Alzheimer's disease. ( Dupre, J; Feleki, V; Fisman, M; Gordon, B; Helmes, E; McDonald, T, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 9 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, JH | 1 |
| Guo, L | 1 |
| Wang, S | 1 |
| Yu, NW | 1 |
| Guo, FQ | 1 |
| Chandan, G | 1 |
| Ganguly, U | 1 |
| Pal, S | 1 |
| Singh, S | 1 |
| Saini, RV | 1 |
| Chakrabarti, SS | 1 |
| Saini, AK | 1 |
| Chakrabarti, S | 1 |
| Sae-Jie, W | 1 |
| Supasai, S | 1 |
| Kivimaki, M | 1 |
| Price, JF | 1 |
| Wong, A | 1 |
| Kumari, M | 1 |
| Engmann, J | 1 |
| Shah, T | 1 |
| Schmidt, AF | 1 |
| Gaunt, TR | 1 |
| Hingorani, A | 1 |
| Charoen, P | 1 |
| Jin, LW | 1 |
| Di Lucente, J | 1 |
| Ruiz Mendiola, U | 1 |
| Suthprasertporn, N | 1 |
| Tomilov, A | 1 |
| Cortopassi, G | 1 |
| Kim, K | 1 |
| Ramsey, JJ | 1 |
| Maezawa, I | 1 |
| Wu, Y | 1 |
| Gong, Y | 1 |
| Luan, Y | 1 |
| Li, Y | 1 |
| Liu, J | 1 |
| Yue, Z | 1 |
| Yuan, B | 1 |
| Sun, J | 1 |
| Xie, C | 1 |
| Li, L | 1 |
| Zhen, J | 1 |
| Jin, X | 1 |
| Zheng, Y | 1 |
| Wang, X | 1 |
| Xie, L | 1 |
| Wang, W | 1 |
| Krishnan, M | 1 |
| Hwang, JS | 1 |
| Kim, M | 1 |
| Kim, YJ | 1 |
| Seo, JH | 1 |
| Jung, J | 1 |
| Ha, E | 1 |
| Jin, N | 1 |
| Ziyatdinova, S | 2 |
| Gureviciene, I | 1 |
| Tanila, H | 2 |
| Shippy, DC | 1 |
| Wilhelm, C | 1 |
| Viharkumar, PA | 1 |
| Raife, TJ | 1 |
| Ulland, TK | 1 |
| Kovács, Z | 1 |
| Brunner, B | 1 |
| Ari, C | 1 |
| Wan, L | 1 |
| Lu, J | 1 |
| Fu, J | 1 |
| Huang, J | 1 |
| Yang, Q | 1 |
| Xin, B | 1 |
| Chen, L | 1 |
| Huo, Y | 1 |
| Zhong, Y | 1 |
| Guo, C | 1 |
| Zhang, J | 1 |
| Cao, Q | 1 |
| Li, S | 1 |
| Lu, X | 1 |
| Zhao, Y | 1 |
| Guan, JS | 1 |
| Chen, JC | 1 |
| Wu, Q | 1 |
| Chen, GQ | 1 |
| Akram, M | 1 |
| Paoli, A | 1 |
| Bianco, A | 1 |
| Damiani, E | 1 |
| Bosco, G | 1 |
| Newport, MT | 1 |
| VanItallie, TB | 1 |
| Kashiwaya, Y | 2 |
| King, MT | 1 |
| Veech, RL | 2 |
| Xie, G | 1 |
| Tian, W | 1 |
| Wei, T | 1 |
| Liu, F | 1 |
| Yin, JX | 1 |
| Maalouf, M | 1 |
| Han, P | 1 |
| Zhao, M | 1 |
| Gao, M | 1 |
| Dharshaun, T | 1 |
| Ryan, C | 1 |
| Whitelegge, J | 1 |
| Wu, J | 1 |
| Eisenberg, D | 1 |
| Reiman, EM | 1 |
| Schweizer, FE | 1 |
| Shi, J | 1 |
| Gibbs, ME | 1 |
| Gibbs, Z | 1 |
| Hertz, L | 1 |
| Zilberter, M | 1 |
| Ivanov, A | 1 |
| Mukhtarov, M | 1 |
| Malkov, A | 1 |
| Alpár, A | 1 |
| Tortoriello, G | 1 |
| Botting, CH | 1 |
| Fülöp, L | 1 |
| Osypov, AA | 1 |
| Pitkänen, A | 1 |
| Harkany, T | 1 |
| Zilberter, Y | 1 |
| Reger, MA | 1 |
| Henderson, ST | 1 |
| Hale, C | 1 |
| Cholerton, B | 1 |
| Baker, LD | 1 |
| Watson, GS | 1 |
| Hyde, K | 1 |
| Chapman, D | 1 |
| Craft, S | 1 |
| Takeshima, T | 1 |
| Mori, N | 1 |
| Nakashima, K | 1 |
| Clarke, K | 1 |
| Fisman, M | 1 |
| Gordon, B | 1 |
| Feleki, V | 1 |
| Helmes, E | 1 |
| McDonald, T | 1 |
| Dupre, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized-controlled Study for Evaluation of Ketogenic Metabolic Nutritional Pattern in Subjects With High-frequency Episodic Migraine[NCT04360148] | 58 participants (Anticipated) | Interventional | 2020-02-06 | Active, not recruiting | |||
| Ketogenic Diet Interventions in Parkinson's Disease: Safeguarding the Gut Microbiome[NCT05469997] | 50 participants (Anticipated) | Interventional | 2023-01-31 | Not yet recruiting | |||
| Ketogenic Diet in McArdle Disease: a Multicentric Single Blind Controlled Trial[NCT04292938] | 16 participants (Actual) | Interventional | 2019-03-25 | Completed | |||
| The Safety and Effects on Whole Organism of Low Energy Ketogenic Diet for Weight Loss in Obese Subjects[NCT03338452] | 38 participants (Actual) | Interventional | 2017-03-18 | Completed | |||
| A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma[NCT05119010] | 60 participants (Anticipated) | Interventional | 2023-03-24 | Recruiting | |||
| A Double-Blind, Placebo-Controlled Study of Tricaprilin (AC-1202) Administered For Ninety Days In Subjects With Age-Associated Memory Impairment[NCT00355550] | Phase 2 | 156 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Safety, Tolerability and Efficacy Study of Tricaprilin (AC-1202) Administered for Ninety Days in Subjects With Probable Alzheimer's Disease of Mild to Moderate Severity[NCT00142805] | Phase 2 | 152 participants (Actual) | Interventional | 2004-11-04 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for 3-hydroxybutyric acid and Alzheimer Disease
| Article | Year |
|---|---|
The potential pharmacological mechanisms of β-hydroxybutyrate for improving cognitive functions.
Topics: 3-Hydroxybutyric Acid; Acetylation; Alzheimer Disease; Amyloid beta-Peptides; Cognition; Humans; Mit | 2022 |
Beneficial Effects of Exogenous Ketogenic Supplements on Aging Processes and Age-Related Neurodegenerative Diseases.
Topics: 3-Hydroxybutyric Acid; Aging; Alzheimer Disease; Diet, Ketogenic; Dietary Supplements; Epigenomics; | 2021 |
A focused review of the role of ketone bodies in health and disease.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Acetone; Alzheimer Disease; Blood Glucose; Diabetic Ketoacidos | 2013 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
1 trial available for 3-hydroxybutyric acid and Alzheimer Disease
| Article | Year |
|---|---|
Effects of beta-hydroxybutyrate on cognition in memory-impaired adults.
Topics: 3-Hydroxybutyric Acid; Aged; Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Brain; Brain C | 2004 |
16 other studies available for 3-hydroxybutyric acid and Alzheimer Disease
| Article | Year |
|---|---|
GLUT inhibitor WZB117 induces cytotoxicity with increased production of amyloid-beta peptide in SH-SY5Y cells preventable by beta-hydroxybutyrate: implications in Alzheimer's disease.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line, Tumor; Glucose; | 2023 |
Triangulating evidence from observational and Mendelian randomization studies of ketone bodies for cognitive performance.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Cognition; Humans; Ketone Bodies; Ketones; Mendelian Rando | 2023 |
The ketone body β-hydroxybutyrate shifts microglial metabolism and suppresses amyloid-β oligomer-induced inflammation in human microglia.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyloid beta-Peptides; Animals; Humans; Inflammation; Keto | 2023 |
BHBA treatment improves cognitive function by targeting pleiotropic mechanisms in transgenic mouse model of Alzheimer's disease.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cell Line; Cognit | 2020 |
β-hydroxybutyrate Impedes the Progression of Alzheimer's Disease and Atherosclerosis in ApoE-Deficient Mice.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Animals; Anti-Inflammatory Agents; Aorta; Apolipoproteins | 2020 |
Response of spike-wave discharges in aged APP/PS1 Alzheimer model mice to antiepileptic, metabolic and cholinergic drugs.
Topics: 3-Hydroxybutyric Acid; Action Potentials; Alzheimer Disease; Animals; Anticonvulsants; Atropine; Dis | 2020 |
β-Hydroxybutyrate inhibits inflammasome activation to attenuate Alzheimer's disease pathology.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Animals; Brain; Female; Humans; Inflammasomes; Male; Mice; | 2020 |
Acetylcholinesterase Inhibitor Donepezil Effects on Plasma β-Hydroxybutyrate Levels in the Treatment of Alzheimer's Disease.
Topics: 3-Hydroxybutyric Acid; Aged; Aged, 80 and over; Alzheimer Disease; Animals; Blood Glucose; Cholester | 2018 |
3-Hydroxybutyrate methyl ester as a potential drug against Alzheimer's disease via mitochondria protection mechanism.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyloid beta-Peptides; Animals; Apolipoproteins E; Apoptos | 2013 |
A new way to produce hyperketonemia: use of ketone ester in a case of Alzheimer's disease.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Dietary Supplements; Glucose; Humans; Hydroxybutyrates; Ke | 2015 |
The neuroprotective effects of β-hydroxybutyrate on Aβ-injected rat hippocampus in vivo and in Aβ-treated PC-12 cells in vitro.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Hippocampus; In | 2015 |
Ketones block amyloid entry and improve cognition in an Alzheimer's model.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognition; | 2016 |
Rescue of Abeta(1-42)-induced memory impairment in day-old chick by facilitation of astrocytic oxidative metabolism: implications for Alzheimer's disease.
Topics: 3-Hydroxybutyric Acid; Acetates; Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Newborn | 2009 |
Dietary energy substrates reverse early neuronal hyperactivity in a mouse model of Alzheimer's disease.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Ani | 2013 |
D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; Alzheimer Disease; Amyloid beta-Peptides; Animal | 2000 |
Metabolic changes in Alzheimer's disease.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Alzheimer Disease; Blood Glucose; Fasting; Humans; Hydroxybuty | 1988 |